COVID-19 Oral Antivirals have transitioned to the Commercial Marketplace
The federal government has shifted COVID-19 oral antiviral treatments Paxlovid (nirmatrelvir packaged with ritonavir) and Lagevrio (molnupiravir) to the commercial market. For information on upcoming milestones and timelines, please refer to:
- Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program
- COVID-19 Therapeutics Transition to Commercial Distribution: Frequently Asked Questions | HHS/ASPR
- DOH Therapeutics Information for Health Care Providers | Washington State Department of Health
Patient and Provider Fact Sheets from ASPR
- Paxlovid (U.S. Office of the Assistant Secretary for Preparedness and Response)
- Lagevrio (Molnupiravir) (ASPR)
- Veklury (remdesivir) (ASPR)
- REGEN-COV (U.S. Office of the Assistant Secretary for Preparedness and Response)
- Sotrovimab (ASPR)
- Evusheld (ASPR)
- Bebtelovimab (ASPR)
Federal Resources
- COVID-19 Therapeutic Product Expiration (U.S. Department of Health and Human Services)
- Claims Reimbursement to Providers and Facilities - Frequently Asked Questions (Health Resources & Services Administration)
- HRSA find a Health Center Program Participants (Health Resources & Services Administration)
Literature
- Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians (Infectious Diseases Society of America)
- Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study (MedRxiv)
- Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients (Oxford Academic)
- Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro (BioRxiv)
- Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment- California, December 2021-May 2022 (CDC)
- Long COVID (CDC)